With regard to BRAF inhibitors, vemurafenib (10–47.8% [33, 34]), dabrafenib (42% [35], data are unavailable specifically for Asia), and encorafenib (5.1–27.3% [36, 37]) induce HFS. Here, BRAF is linked to Hand-foot syndrome.